Navigation Links
Cambrex Reports Third Quarter 2008 Results
Date:11/4/2008

ed EBITDA for the quarter. While general business conditions have impacted the number and timing of new custom development projects, especially those in the early clinical stages of development, the Company has a strong pipeline of late- stage Phase III projects. In addition, we continue to see solid growth in our controlled substances products. Softer market conditions, along with the previously reported impact of a customer recall, have resulted in lower than expected year-to-date results and ultimately a moderate downward revision in our full year earnings guidance.

"We are nearing completion of our new mid-scale API manufacturing facility at our Swedish operation, which is expected to be on line in early 2009, and production has started in a portion of our state of the art API finishing facility in Milan, Italy, with the remainder in the later stages of validation. Along with our new high potency development center in Iowa, the completion of these projects cap a three year period of higher than normal capital investments and position us well for future growth.

"We were pleased with the positive cash generation in the third quarter net of the impact of foreign exchange. We will continue to aggressively cut costs and focus on increasing cash flow in 2009 and beyond.

"We have nearly three and a half years remaining on our $200 million revolving credit facility and believe that cash flows from operations, along with funds available from this facility, will provide more than enough capital to execute our plan over the next few years of aggressively growing sales of products based on our proprietary drug delivery and tastemasking technologies, controlled substances, new generic APIs, and the transition of late stage clinical projects to long term supply agreements."

Third Quarter 2008 Operating, Interest and Tax Expenses - Continuing Operations

SG&A Expenses in the third quarter 2008 were $8.8 million compared to $10.7 million in the
'/>"/>

SOURCE Cambrex Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Cambrex Presentation at the JPMorgan Healthcare Conference to be Webcast
2. Cambrex to Announce Fourth Quarter and Full Year 2007 Financial Results on February 14, 2008
3. Cambrex Appoints Steven M. Klosk as President and CEO
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. QMed, Inc. Reports July Medicare SNP Enrollments
6. Phlo Affiliate Reports Expanded Coverage to Oregon Border
7. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
8. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
9. Carrington Reports Second Quarter 2007 Results
10. Avitar Reports Third Quarter Financial Results for Fiscal 2007
11. Response Genetics Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014 In preparation for VARTECH 2014, ... cybersecurity company focused on authentication and SSO announced today ... ability to generate a OTP through the presentation of ... of user-based RFID authentication, 2FA,s solutions have leveraged the ... many years. RFID authentication is broadly deployed in healthcare ...
(Date:9/16/2014)... 16, 2014 According to Jeff Howell, ... of ITRA Global, new development in Downtown Toronto is ... council approving another 755 storeys of new development last ... cranes will be dominating the Toronto skyline for the ... an unquenchable thirst for new development. , As the ...
(Date:9/15/2014)... solid, liquid, and gasbut much stranger things ... phase transitions occur at the coldest temperatures ... can dramatically transform a material. , ... Brookhaven National Laboratory and Stony Brook University ... zero to isolate and probe these quantum ...
(Date:9/15/2014)... Cancer Immunotherapy Market : ... Therapies is a new market research report announced ... principal types of therapeutics that have become the ... immunotherapy (which is often called "immuno-oncology") in recent ... cellular immunotherapy. , The regular use of ...
Breaking Biology Technology:2FA, Inc. Announces RFID-based One-Time Password (OTP) Authentication 2ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 2ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 3Elusive quantum transformations found near absolute zero 2Elusive quantum transformations found near absolute zero 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5
... eResearchTechnology, Inc. (ERT), (Nasdaq: ERT ) a ... to bio-pharmaceutical and healthcare organizations and the market leader ... drug development, announced today that its Board of Directors ... and Chief Executive Officer and as a member of ...
... Biopharmaceuticals, Inc. (NASDAQ: KERX ), a biopharmaceutical ... medically important pharmaceutical products for the treatment of cancer ... for the first quarter ended March 31, 2011. ... cash equivalents and investment securities of $23.1 million, as ...
... 2011 Frost & Sullivan Europe New Product Innovation Award ... for its state-of-the-art, high precision Novelda Impulse Radar transceiver ... Radar transceiver is a cutting-edge radar transceiver that incorporates ... unique penetration capabilities," remarks Frost & Sullivan Research Analyst ...
Cached Biology Technology:ERT Announces Appointment of New President and CEO 2ERT Announces Appointment of New President and CEO 3ERT Announces Appointment of New President and CEO 4Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results 3Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results 4Frost & Sullivan Award Acknowledges Novelda's Cutting-Edge Product Innovation 2Frost & Sullivan Award Acknowledges Novelda's Cutting-Edge Product Innovation 3Frost & Sullivan Award Acknowledges Novelda's Cutting-Edge Product Innovation 4
(Date:9/16/2014)... PALM BEACH GARDENS, Fla. , Sept. 16, ... provider of biometric identity management solutions, announced today ... handheld solution designed to authenticate the identity of ... The Android-based Verifier Sentry rapidly reads ... the credential holder,s ID by matching the biometric ...
(Date:9/15/2014)... processes from digestion to disease resistance. Despite the fact ... on the planet, more is known about belly-button bacteria ... and colleagues working on Panama,s Barro Colorado Island discovered ... home to more than 400 different kinds of bacteria. ... than 7,000 different kinds. , Bacteria in tropical forests ...
(Date:9/15/2014)... has evolved a simple, mechanical solution to avoid ... 11 Science Express. , ... misalignments that lead to infertility, miscarriage, or congenital ... cause these problems, but what exactly goes wrong ... the Wellcome Trust Center for Cell Biology at ...
Breaking Biology News(10 mins):Cross Match Launches New Identity Management Handheld Solution 2Smithsonian scientists discover tropical tree microbiome in Panama 2Cells simply avoid chromosome confusion 2Cells simply avoid chromosome confusion 3
... go through a laboratory version of boot camp may ... of Pittsburgh researchers. In essence, that's the concept behind ... a patient's own souped up dendritic cells, which have ... system in fighting the virus unique to that individual. ...
... affiliate of Harvard Medical School, are the first to ... angiogenesis (new blood vessel growth). The switch, they learned, ... two enzymes (known as PI3K and PLCg) that compete ... fulfill opposite missions, growth and regression, respectively. This finding ...
... at the Harvard Department of Ophthalmology's Schepens Eye Research ... the first to learn why the cornea, the clear ... unique phenomenon that makes vision possible. The key, say ... of the protein VEGFR-3 (vascular endothelial growth factor receptor-3) ...
Cached Biology News:T cells activated to fight HIV basis for dendritic cell therapeutic vaccine 2T cells activated to fight HIV basis for dendritic cell therapeutic vaccine 3Schepens scientists are first to discover angiogenesis switch inside blood vessel cells 2Schepens scientists are first to discover angiogenesis switch inside blood vessel cells 3Scientists discover why cornea is transparent and free of blood vessels, allowing vision 2Scientists discover why cornea is transparent and free of blood vessels, allowing vision 3
Rabbit Anti-Mouse Ym1 Polyclonal Antibody,...
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
... of large numbers of samples may be carried ... which requires minimum operator attention. System control ... and interface CE 4900. The elegant, powerful ... Windows XP and Windows 98 and 2000., The ...
... This system uses the Adept CE 4100 ... Ultra-Fast Scanning UV/Visible detector for added flexibility and ... a trustworthy alternative to a photodiode array detection ... one detector is required for method development and ...
Biology Products: